HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models

[1]  Yongping Song,et al.  SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don’t eat me” signal and activating the “eat me” signal , 2022, Journal of Hematology & Oncology.

[2]  Y. Kong,et al.  A Multicenter, Single-Arm, Phase II Trial of RC48-ADC Combined with Radiotherapy, PD-1/PD-L1 Inhibitor Sequential GM-CSF and IL-2 (PRaG3.0 regimen) for the Treatment of HER2-Expressing Advanced Solid Tumors , 2022, International Journal of Radiation Oncology*Biology*Physics.

[3]  L. Miller,et al.  Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response , 2022, Journal for immunotherapy of cancer.

[4]  R. Akbani,et al.  Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma. , 2022, Cancer cell.

[5]  M. Cam,et al.  Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice , 2022, Oncoimmunology.

[6]  Zhichen Sun,et al.  Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity , 2022, The Journal of clinical investigation.

[7]  J. Minna,et al.  Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors , 2021, Science Translational Medicine.

[8]  E. Yang,et al.  Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers , 2021, Vaccines.

[9]  Wang Jing,et al.  Anlotinib in combination with TQB2450 in patients with recurrent ovarian cancer (ACTION): A multicenter, single-arm, open-label, phase Ib trial. , 2021 .

[10]  Shuiping Gao,et al.  Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors , 2021, Therapeutic advances in medical oncology.

[11]  Jianming Xu,et al.  Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial , 2020, Oncoimmunology.

[12]  Yunpeng Liu,et al.  HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial , 2020, Journal for ImmunoTherapy of Cancer.

[13]  I. Weissman,et al.  Targeting macrophage checkpoint inhibitor SIRPa for anticancer therapy. , 2020, JCI insight.

[14]  K. Akashi,et al.  Combination of CD47 and signal‐regulatory protein‐α constituting the “don’t eat me signal” is a prognostic factor in diffuse large B‐cell lymphoma , 2020, Cancer science.

[15]  I. Weissman,et al.  Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies , 2020, Frontiers in Oncology.

[16]  Ying Huang,et al.  HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties , 2020, mAbs.

[17]  L. Ridnour,et al.  Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation , 2019, Cancer Immunology, Immunotherapy.

[18]  Betty Y. S. Kim,et al.  Phagocytosis checkpoints as new targets for cancer immunotherapy , 2019, Nature Reviews Cancer.

[19]  Chuang Chen,et al.  Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients , 2019, Cancer Cell International.

[20]  Bo Peng,et al.  Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit , 2019, mAbs.

[21]  Chuang Chen,et al.  High expression of CD47 in triple negative breast cancer is associated with epithelial-mesenchymal transition and poor prognosis , 2019, Oncology letters.

[22]  Y. Xi,et al.  Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia. , 2019, Pathology, research and practice.

[23]  Yijian Li.  CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma. , 2019, The New England journal of medicine.

[24]  I. Weissman,et al.  CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma , 2018, The New England journal of medicine.

[25]  Demin Zhou,et al.  Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry. , 2018, Journal of visualized experiments : JoVE.

[26]  Sheng Guo,et al.  The design, analysis and application of mouse clinical trials in oncology drug development , 2018, BMC Cancer.

[27]  C. Querfeld,et al.  Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience , 2018, Current opinion in oncology.

[28]  yang-xin fu,et al.  Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. , 2018, Cell reports.

[29]  K. Tarte,et al.  Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia , 2018, Molecular Cancer Therapeutics.

[30]  Juanjuan Su,et al.  Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice , 2018, Cell Research.

[31]  Ya-jun Guo,et al.  Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses , 2018, mAbs.

[32]  S. Rodig,et al.  Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. , 2017, Blood advances.

[33]  Hongliang Yu,et al.  Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model. , 2017, Oncology research.

[34]  V. Lee,et al.  TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets , 2017, PloS one.

[35]  Junzhi Wang,et al.  Development of a robust reporter gene assay to measure the bioactivity of anti‐PD‐1/anti‐PD‐L1 therapeutic antibodies , 2017, Journal of pharmaceutical and biomedical analysis.

[36]  Qi-Xiang Li,et al.  Experimental animal modeling for immuno-oncology. , 2017, Pharmacology & therapeutics.

[37]  Zihai Li,et al.  Is CD47 an innate immune checkpoint for tumor evasion? , 2017, Journal of Hematology & Oncology.

[38]  Qi-Xiang Li,et al.  Molecular Pathology of Patient Tumors, Patient-Derived Xenografts, and Cancer Cell Lines. , 2016, Cancer research.

[39]  I. Weissman,et al.  First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Majeti,et al.  SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells , 2016, Clinical Cancer Research.

[41]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[42]  J. Wery,et al.  A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations , 2015, Oncotarget.

[43]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[44]  yang-xin fu,et al.  CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors , 2015, Nature Medicine.

[45]  S. Ansell.  Targeting immune checkpoints in lymphoma , 2015, Current opinion in hematology.

[46]  R. Majeti,et al.  A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells , 2015, mAbs.

[47]  G. Freeman,et al.  The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. , 2015, Clinical therapeutics.

[48]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[49]  J. Berzofsky,et al.  CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. , 2014, Cancer research.

[50]  K. Akashi,et al.  The BALB/c-specific polymorphic SIRPA enhances its affinity for human CD47, inhibiting phagocytosis against human cells to promote xenogeneic engraftment. , 2014, Experimental hematology.

[51]  K. Akashi,et al.  Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment. , 2013, Blood.

[52]  Junjie Lu,et al.  Overcoming erlotinib resistance with tailored treatment regimen in patient‐derived xenografts from naïve Asian NSCLC patients , 2013, International journal of cancer.

[53]  Aik Choon Tan,et al.  Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.

[54]  I. Weissman,et al.  Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells , 2012, Leukemia.

[55]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[56]  Ash A. Alizadeh,et al.  Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. , 2011, Cancer research.

[57]  Ash A. Alizadeh,et al.  Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma , 2010, Cell.

[58]  M. Caligiuri,et al.  Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. , 2005, Blood.

[59]  Demin Zhou,et al.  In Vivo Pharmacology Models for Cancer Target Research. , 2019, Methods in molecular biology.